Fmoc-L-Orn(Z)-OH

Fmoc-L-Orn(Z)-OH is an Fmoc-protected L-ornithine derivative bearing a Z (benzyloxycarbonyl) protecting group on the side-chain amino functionality, furnishing a chiral amino acid building block with two orthogonally protected nitrogen sites. The molecule contains an N-(9H-fluoren-9-ylmethoxycarbonyl) carbamate at the α-amino position and a benzyloxycarbonyl-protected ε-amino group, together with a free carboxylic acid for coupling chemistry. The preserved L-stereochemistry at the α-carbon and the orthogonal protection pattern enable controlled deprotection sequences, while the benzyl-derived Z group provides stability under many peptide coupling conditions and can be removed under hydrogenolysis-compatible strategies. The resulting reactivity profile supports stepwise peptide assembly and downstream derivatization of the ornithine side chain into amide, urea, or further functionalized nitrogen-containing motifs.

1. Peptide Synthesis

Fmoc-L-Orn(Z)-OH is used in solid-phase peptide synthesis and automated peptide assembly where orthogonally protected ornithine residues are required to control side-chain chemistry during chain elongation. The Fmoc carbamate on the α-amino group enables standard base-labile Fmoc removal to expose the coupling-ready amine, while the Z-protected side-chain ε-amine remains masked to prevent premature crosslinking or branching. The free carboxylic acid participates in amide bond formation, allowing incorporation into peptide sequences that demand selective post-assembly functionalization at the ornithine side chain. The resulting protected amino acid derivative supports construction of cationic, polyamine-derived peptide segments and can be carried through iterative cycles to yield well-defined peptide architectures for biochemical research and analytical reference materials.

2. Side-Chain Functionalization

Fmoc-L-Orn(Z)-OH serves as a controlled precursor for ornithine side-chain modification strategies that convert the protected ε-amino group into tailored functional handles after peptide assembly. The Z-protected nitrogen can be preserved through peptide coupling steps and then selectively deprotected to reveal a primary amine positioned for acylation, sulfonylation, or urea formation, enabling introduction of linkers, affinity tags, or solubilizing substituents. The orthogonal protection pattern supports sequential transformations in which the α-amino site is managed by Fmoc chemistry while the side-chain nitrogen is addressed independently, improving compatibility with multi-step synthetic routes. Downstream derivatives can include ornithine-containing peptidomimetics, charge-tuned peptide analogs, and conjugation-ready intermediates used in chemical biology and materials-oriented molecular design.

3. Bioconjugation Chemistry

Fmoc-L-Orn(Z)-OH is applicable to bioconjugation workflows that require defined incorporation of an ornithine-derived amine for site-selective attachment of biomolecule-reactive moieties. The protected ε-amine reduces side reactions during peptide synthesis and purification, while the eventual unveiling of the primary amine enables formation of stable linkages such as amide bonds or other nitrogen-directed conjugation products. The carboxylic acid functionality and peptide-compatible protection scheme allow the residue to be integrated into peptide carriers, affinity peptides, or labeling scaffolds prior to conjugation. Resulting conjugate precursors can be used to generate labeled biomolecular probes, immobilized peptide ligands, and structured chemical handles for downstream binding studies and analytical characterization.

4. Peptidomimetics And SAR Studies

Fmoc-L-Orn(Z)-OH supports peptidomimetic construction and structure-activity relationship studies by enabling incorporation of an ornithine stereocenter and a protected side-chain amine into constrained peptide-like scaffolds. The L-configuration at the α-carbon helps maintain stereochemical fidelity when mapping sequence or side-chain effects on binding and recognition properties in SAR-focused libraries. The controlled deprotection sequence, enabled by Fmoc and Z orthogonality, allows generation of analog series with systematic side-chain modifications without perturbing the backbone during synthesis. The resulting ornithine-bearing intermediates can feed combinatorial synthesis and fragment-based optimization campaigns that rely on consistent stereochemistry and reproducible functional group placement.

5. Pharmaceutical Manufacturing Intermediates

Fmoc-L-Orn(Z)-OH can be employed in pharmaceutical manufacturing settings as a protected amino acid intermediate for producing ornithine-containing peptides and peptide-derived building blocks used in process chemistry. The Fmoc-protected α-amino group and Z-protected side-chain amine provide a manufacturable protection strategy that supports predictable coupling behavior and minimizes undesired side reactions during scale-up peptide assembly. The free carboxylic acid enables standard peptide coupling operations in a downstream manufacturing route, while orthogonal deprotection potential supports controlled generation of reactive amine functionality for further conversion into drug substance-related intermediates. The compound's defined stereochemistry and protection-group architecture make it suitable for consistent intermediate preparation in fine chemical production workflows where peptide quality attributes depend on sequence fidelity and functional group integrity.

1. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

2. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

3. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

5. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling